A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
PHASE2RecruitingINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
September 23, 2022
Primary Completion Date
January 30, 2026
Study Completion Date
January 30, 2026
Conditions
Large B-cell LymphomaLymphoma
Interventions
DRUG
Loncastuximab Tesirine
Given by IV
Trial Locations (1)
77030
RECRUITING
MD Anderson Cancer Center, Houston
All Listed Sponsors
lead
M.D. Anderson Cancer Center
OTHER
NCT05464719 - A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy | Biotech Hunter | Biotech Hunter